The market for cannabidiol (CBD) products is booming, with a variety of related substances such as cannabigerol (CBG), which stands out for its therapeutic and non-psychoactive properties. In this article, we will focus on the important role of CBG in balancing the endocannabinoid system.
What is Cannabigerol (CBG)?
CBG is a naturally occurring chemical compound foundin the cannabis plant, just like CBD. Unlike tetrahydrocannabinol (THC), which is responsible for the psychotropic effects, CBG does not cause intoxication or psychoactive effects. It is often referred to as a “regulating cannabinoid” because of its modulating action on other cannabinoids, particularly THC and CBD. CBG was first discovered in 1964 by Yehiel Gaoni and Raphael Mechoulam, two Israeli researchers. Since then, numerous studies have highlighted its potential therapeutic benefits.
Therapeutic potential of CBG
Recent research has revealed that CBG has several medicinal properties, including:
- Anti-inflammatory: CBG may help reduce inflammation and pain associated with conditions such as arthritis and inflammatory bowel disease.
- Antibacterial: Studies have shown that CBG possesses significant antibacterial activity, capable of fighting bacteria resistant to common drugs.
- Antimicrobial: Similar to its antibacterial activity, CBG also exhibits promising antimicrobial properties that could be used to treat various infections.
- Neuroprotective: CBG may play a role in protecting nerve cells from damage, thus helping to prevent or mitigate the effects of neurodegenerative diseases such as multiple sclerosis or Alzheimer's disease.
Role of CBG in the endocannabinoid system
The endocannabinoid system (ECS) is a complex network of compounds and receptors in the body that play a crucial role in regulating many essential processes, such as the immune response, memory, mood, and pain perception. Endogenous (produced by our bodies) and exogenous (derived from cannabis) cannabinoids interact with these receptors to modulate these functions.
Unlike other cannabinoids, CBG has a low affinity for the CB1 and CB2 receptors of the endocannabinoid system (ECS). Therefore, it acts primarily as an indirect modulator, acting on other non-cannabinoid receptors such as PPARγ or 5-HT1A receptors. This modulating capacity gives CBG significant importance in regulating the effects of other cannabinoids, particularly in mitigating the psychoactive properties of THC and amplifying the therapeutic benefits of CBD.
Entourage effect: synergy between CBG and other cannabinoids
The“entourage effect” is a concept that suggests cannabinoids work better together than in isolation. This holistic approach to cannabis products suggests that substances present in these extracts, such as terpenes and flavonoids, interact synergistically with cannabinoids to enhance their effectiveness and diversify their therapeutic applications.
- Mitigation of psychoactive effects: CBG can reduce the undesirable psychoactive effects of THC by inhibiting its activity on CB1 receptors, while still allowing you to benefit from its medicinal properties.
- Amplification of therapeutic benefits: The combination of CBG and CBD may have greater therapeutic potential than CBD alone, thanks to the modulation of non-cannabinoid receptors and the interactions between these two cannabinoids.
In conclusion, CBG is a key molecule for understanding the mechanisms of action of other cannabinoids and thus maximizing their benefits. With further research into its properties and its role within the endocannabinoid system, the future of CBG looks promising for the development of new cannabis-derived treatments and wellness products.
Sources
- https://www.mariefrance.fr/equilibre/sante/quelles-sont-les-informations-a-connaitre-sur-le-cbd-le-hhc-le-h4cbd-le-cbg-et-le-cbn-800790.html
- https://www.newsweed.fr/cannabis/cannabigerol/
Co-founder of CBD.fr
Julien Cordobes is the editor of CBD.fr. Born in 1978 in the Paris region, he first trained in e-commerce before turning to natural health approaches, a dual perspective that now structures his way of writing about cannabidiol: reading the scientific literature as it is, without hardening the conclusions, and presenting it in a language that everyone understands.
He discovered CBD at a time when the French market was developing faster than the information available to it. He acquired CBD.fr in 2022 and then took on editorial responsibility for the blog. Since then, he has published numerous articles covering the daily use of CBD, the interpretation of laboratory analyses, the evolution of the legal framework, and precautions for use.
